货号:A143592
同义名:
盐酸胺碘酮
/ Amiodarone (hydrochloride); Amiodarone hydrochloride
Amiodarone HCl 是一种抗心律失常化合物,用于抑制ATP敏感的钾通道,IC50为19.1 μM。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK1, IC50: 108 nM ULK2, IC50: 711 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | Potassium Channel ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tolbutamide | ✔ | 98% | |||||||||||||||||
| Glimepiride |
++++
SUR2B, IC50: 7.3 nM SUR1, IC50: 5.4 nM |
97% | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Gliquidone |
++
Potassium channel, IC50: 27.2 nM |
99% | |||||||||||||||||
| TRAM-34 |
+++
IKCa1 (KCa3.1), Kd: 20 nM |
98% | |||||||||||||||||
| Glibenclamide | ✔ | 98% | |||||||||||||||||
| Amiodarone HCl | ✔ | 97% | |||||||||||||||||
| Gliclazide |
++
Potassium channel, IC50: 184 nM |
98% | |||||||||||||||||
| Repaglinide | ✔ | 98% | |||||||||||||||||
| Dofetilide | ✔ | 98% | |||||||||||||||||
| Nateglinide | ✔ | 99% | |||||||||||||||||
| Quinine HCl dihydrate | ✔ | 98% | |||||||||||||||||
| ML133 HCl |
+
Kir2.1, IC50: 290 nM |
99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Amiodarone hydrochloride is an antiarrhythmic drug for inhibition of ATP-sensitive potassium channel with IC50 of 19.1 μM. Amiodarone may act as an antioxidant/antiatherosclerotic agent in humans[3]. Amiodarone stimulates the accumulation of ethidium bromide by inhibiting its efflux from the cells. The effect of amiodarone is much stronger on wild-type cells compared to the mutant with inactivated ABC-transporters[4]. Chronic treatment with oral amiodarone for 4 weeks reduced Ip when myocytes were dialyzed with patch-pipettes containing either 10 mM Na+ or 80 mM Na+. Amiodarone had no effect on the voltage dependence of the pump or the affinity of the pump for extracellular K+ either after chronic treatment or during acute exposure. An amiodarone-induced inhibition of the hyperpolarizing Na(+)-K+ pump current may contribute to the action potential prolongation observed during treatment with this drug[5]. Cells treated with amiodarone were seen to have detached from the dish, with cell rounding, cytoplasmic blebbing and irregularity in shape. An increase in the sub-G1 phase fraction, from 15.43 to 21.34% and 79.83% and a reduction in the G1 phase fraction, from 48.83 to 41.63% and 11.52%, were observed in cells treated with amiodarone at concentrations of 0.1 and 1 mM, respectively[6]. |
| Concentration | Treated Time | Description | References | |
| CAFs | 2.5 μM | 24 h | To evaluate the effect of Amiodarone on the activated state of CAFs, results showed that Amiodarone partially reversed the activated state of CAFs and reduced the protumor effects of CAFs on PCa cell growth. | J Exp Clin Cancer Res. 2024 Jun 11;43(1):161. |
| DU145 cells | 2.5 μM | 24 h | To evaluate the effect of Amiodarone on the growth of DU145 cells, results showed that Amiodarone reduced the protumor effects of CAFs on DU145 cell growth. | J Exp Clin Cancer Res. 2024 Jun 11;43(1):161. |
| BEAS-2B cells | 1, 3, 9 μM | 24 h | Amiodarone significantly decreased the viability of BEAS-2B cells, increased LDH release, ROS generation, caspase 3 activation, and apoptosis. | Redox Rep. 2025 Dec;30(1):2447721. |
| BEAS-2B cells | 3 μM | 24 h | Amiodarone significantly induced ROS generation and mitochondrial membrane potential depolarization in BEAS-2B cells, while artemisinin pretreatment significantly inhibited these effects. | Redox Rep. 2025 Dec;30(1):2447721. |
| BEAS-2B cells | 3 μM | 24 h | Amiodarone significantly increased caspase 3 activity and apoptosis in BEAS-2B cells, while artemisinin pretreatment significantly inhibited these effects. | Redox Rep. 2025 Dec;30(1):2447721. |
| RAW 264.7 cells | 0.312 μM | 1, 3, 5, 7 days | To investigate the effect of amiodarone on BMP accumulation in RAW 264.7 cells, the results showed that amiodarone treatment significantly increased cellular BMP levels. | J Lipid Res. 2024 Jul;65(7):100574. |
| NR8383 rat alveolar macrophages | 5 µM | 24 h | To evaluate the effects of Amiodarone on macrophage morphology and function, the results showed that amiodarone-induced foamy macrophages displayed characteristics of proinflammatory macrophages, including significantly increased nitric oxide production, vacuolation and lipidosis, and decreased phagocytic activity. | Front Immunol. 2021 Sep 1;12:611280. |
| A549 cells | 0.16-10 μM | 24 h | Test whether Amiodarone induces phospholipidosis, results showed Amiodarone significantly induced NBD-PE fluorescence, while sangivamycin did not. | JCI Insight. 2022 Jan 11;7(1):e153165. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | C57BL/6J mice | Oral | 300 mg/kg | 5 times per week for 4 weeks | To study the amiodarone-induced interstitial lung disease (ILD) model, results showed that amiodarone caused a gradual decrease in in mice, with macrophage infiltration observed in the lungs, while co-treatment with dabigatran significantly attenuated these changes. | Front Pharmacol. 2021 Sep 21;12:635293 |
| SCID mice | PCa xenograft model | Intratumoral injection | 250 μl | 5 consecutive days for 2 weeks | To evaluate the effect of Amiodarone on the growth of PCa xenograft tumors, results showed that Amiodarone reduced the protumor effects of CAFs on tumor growth. | J Exp Clin Cancer Res. 2024 Jun 11;43(1):161. |
| Mice | Awake and freely moving CD-1 male mice | Intraperitoneal injection | 5 mg/kg | Single administration, observed for 6 hours | Amiodarone did not revert the JWH-018-induced bradycardia but reduced tachyarrhythmic events, completely suppressing them during the last three hours of the experiment. Additionally, amiodarone slightly reverted the JWH-018-induced vasoconstriction during the fourth hour and restored the breathing rate reduction caused by JWH-018. | Int J Mol Sci. 2023 Apr 19;24(8):7515 |
| C57Bl6/J mice | Amiodarone-induced lung injury model | Tracheal injection | 3 mg/kg | Single injection | Amiodarone significantly increased TUNEL-positive cells and cleaved caspase 3 protein levels in the lung tissue of mice, while artemisinin pretreatment significantly inhibited these effects and increased p-AMPK and Nrf2 protein levels. | Redox Rep. 2025 Dec;30(1):2447721. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02814903 | - | Unknown | August 2017 | France ... 展开 >> Joachim ALEXANDRE Recruiting Caen, Basse Normandie, France, 14000 Contact: Mathieu CHEQUEL, MD +33625342363 chequel-m@chu-caen.fr Contact: Pierre OLLITRAULT, MD +33624922671 ollitrault-p@chu-caen.fr 收起 << | |
| NCT03685149 | Arrhythmogenic Right Ventricul... 展开 >>ar Cardiomyopathy 收起 << | Phase 2 | Not yet recruiting | August 2020 | United States, New York ... 展开 >> University of Rochester Medical Center Not yet recruiting Rochester, New York, United States, 14642 Contact: Spencer Rosero, MD 585-275-4775 spencer_rosero@urmc.rochester.edu Contact: Laura Wing 585-273-4128 laura_wing@urmc.rochester.edu 收起 << |
| NCT00589303 | - | Terminated(Lack of funding) | - | - | |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.47mL 0.29mL 0.15mL |
7.33mL 1.47mL 0.73mL |
14.67mL 2.93mL 1.47mL |
|
| CAS号 | 19774-82-4 |
| 分子式 | C25H30ClI2NO3 |
| 分子量 | 681.77 |
| SMILES Code | CCCCC1=C(C(C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)=O)C3=C(O1)C=CC=C3.Cl |
| MDL No. | MFCD00069204 |
| 别名 | 盐酸胺碘酮 ;Amiodarone (hydrochloride); Amiodarone hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | ITPDYQOUSLNIHG-UHFFFAOYSA-N |
| Pubchem ID | 441325 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 20 mg/mL(29.34 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1